Hemera
  • Company
    • About us
    • Team
    • Job opportunities
  • Cell therapy
    • REMaST®️
    • Preclinical results
    • Clinical trials
    • Publications
  • Newsroom
    • Highlights
    • News and events
    • Videos
    • Interviews
  • Investors
  • English
    • Italiano (Italian)
Select Page

REMaST® and the Immunity publication: growing media attention around the REMaST® therapeutic platform and its clinical development

Feb 26, 2026 | News, Press Review

From TG3 Leonardo to national media: press recognition supports Hemera’s path toward the clinical phase Following the recent publication in the prestigious international journal  Immunity by Cell Press of data related to the REMaST® cell therapy, Hemera is pleased to...

Reprogrammed Macrophage Research REMaST® presented at International Symposium in Houston

Feb 20, 2026 | Events, News

At the 2026 International Cancer Neuroscience Symposium in Houston (USA) the prestigious scientific forum organized by MD Anderson Cancer Center and Advanced Portfolio, Professor Francesco Bifari, co-founder and Director of Therapy Development at Hemera, was invited...

Hemera featured on the cover of Immunity: full version of the REMaST® study published

Feb 11, 2026 | News, Press Releases

Immunity by Cell Press dedicates the cover of Volume 59, Issue 2,10 February 2026 to our study reporting the preclinical data underpinning the REMaST® therapeutic platform. Cristiana Vignoli, CEO of Hemera, stated:“The cover of Immunity confirms the value of Italian...

Hemera announces the publication in Immunity of preclinical discoveries on REMaST® for neural tissue regeneration

Jan 26, 2026 | News, Press Releases

A peer-reviewed study demonstrates the therapeutic potential of REMaST® in spinal cord repair and neuronal regeneration Hemera is pleased to announce the online preprint publication of the manuscript “Tumor-associated macrophages enhance peripheral nerve tumor...

Published in STAR Protocols: Severe contusive preclinical model confirms the preclinical value of REMaST®

Dec 28, 2025 | News

Researchers at Hemera, including co-founders Ilaria Decimo and Francesco Bifari and senior scientist Sissi Dolci, have published a key study in STAR Protocols by Cell Press, essential for the development of REMaST®, our advanced cell therapy for nervous tissue...

Cristiana Vignoli and Hemera’s Entrepreneurial Vision Featured in Il Sole 24 Ore

Dec 15, 2025 | News

Il Sole 24 Ore insert dedicated to the BFactor Award by the Fondazione Marisa Bellisario was released, featuring a profile of the winners. Among them, Cristiana Vignoli, CEO of Hemera, shared her entrepreneurial vision and the journey that led to the development of...
« Older Entries

Follow us on social:

  • Follow
  • Follow
  • Follow

HÊMERA SRL

Via Giovanni della Casa, 26
37122 Verona – Italy
VAT IT04819260235
REA: VR – 448793
Mail: info@hemerapharma.com
PEC: hemera@pec.it
Web: hemerapharma.com

OPERATIONAL HEADQUARTERS VERONA

Dipartimento di Diagnostica e Sanità pubblica. Palazzina Medicina Legale – Farmacologia – CIRSAL.

Piazzale L. Scuro, 10 – 37134 Verona (VR)

OPERATIONAL HEADQUARTERS MILAN

Dipartimento di Biotecnologie Mediche e Medicina Traslazionale – BIOMETRA. Laboratorio Interdisciplinare di Tecnologie Avanzate (LITA).

Via Fratelli Cervi, 93 – 20054 Segrate (MI)

Privacy Policy | Cookies policy | Modifica preferenze
Copyright Hemera Srl © 2026
FAQ | Contacts